Literature DB >> 22284801

Psychopharmacology of autism spectrum disorders.

Gabriel Kaplan1, James T McCracken.   

Abstract

At present, no evidence-based effective pharmacologic options are available for treating the core deficits of autism spectrum disorders (ASDs), which are best addressed by behavioral and educational interventions. However, such evidence exists for several of the frequently associated/comorbid symptoms such as aggression and severe irritability, hyperactivity, and repetitive behaviors, which can become a major source of additional distress and interference in functioning. This article offers information on the psychopharmacology of ASD that is current, relevant, and organized in a user-friendly manner, to form a concise but informative reference guide for primary pediatric clinicians.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284801     DOI: 10.1016/j.pcl.2011.10.005

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  13 in total

1.  Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Authors:  Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook
Journal:  Pharmacogenet Genomics       Date:  2015-11       Impact factor: 2.089

2.  Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder.

Authors:  Johanna K Lake; Danica Denton; Yona Lunsky; Amy M Shui; Jeremy Veenstra-VanderWeele; Evdokia Anagnostou
Journal:  J Autism Dev Disord       Date:  2017-05

Review 3.  Efficacy of early interventions for infants and young children with, and at risk for, autism spectrum disorders.

Authors:  Rebecca J Landa
Journal:  Int Rev Psychiatry       Date:  2018-03-14

4.  The Prevalence of Parent-Reported Autism Spectrum Disorder Among US Children.

Authors:  Michael D Kogan; Catherine J Vladutiu; Laura A Schieve; Reem M Ghandour; Stephen J Blumberg; Benjamin Zablotsky; James M Perrin; Paul Shattuck; Karen A Kuhlthau; Robin L Harwood; Michael C Lu
Journal:  Pediatrics       Date:  2018-12       Impact factor: 7.124

5.  Awareness and Knowledge of Autism Spectrum Disorders Among Pharmacists: A Cross-Sectional Study in Palestinian Pharmacy Practice.

Authors:  Ramzi Shawahna; Basel Fahed; Dana Qadri; Lamees Sharawi; Mai Soroghli; Maen Dweik
Journal:  J Autism Dev Disord       Date:  2017-06

6.  Social-like responses are inducible in asocial Mexican cavefish despite the exhibition of strong repetitive behavior.

Authors:  Motoko Iwashita; Masato Yoshizawa
Journal:  Elife       Date:  2021-09-20       Impact factor: 8.140

7.  Many Young Children with Autism Who Use Psychotropic Medication Do Not Receive Behavior Therapy: A Multisite Case-Control Study.

Authors:  Lisa D Wiggins; Cy Nadler; Steven Rosenberg; Eric Moody; Nuri Reyes; Ann Reynolds; Aimee Alexander; Julie Daniels; Kathleen Thomas; Ellen Giarelli; Susan E Levy
Journal:  J Pediatr       Date:  2021-01-22       Impact factor: 6.314

8.  Adverse effects of risperidone in children with autism spectrum disorders in a naturalistic clinical setting at siriraj hospital, Thailand.

Authors:  Vitharon Boon-Yasidhi; Pantipa Jearnarongrit; Patnaree Tulayapichitchock; Jariya Tarugsa
Journal:  Psychiatry J       Date:  2014-02-03

9.  Mixed housing with DBA/2 mice induces stress in C57BL/6 mice: implications for interventions based on social enrichment.

Authors:  Natalia Kulesskaya; Nina N Karpova; Li Ma; Li Tian; Vootele Voikar
Journal:  Front Behav Neurosci       Date:  2014-08-06       Impact factor: 3.558

10.  The evolution of a series of behavioral traits is associated with autism-risk genes in cavefish.

Authors:  Masato Yoshizawa; Alexander Settle; Meredith C Hermosura; Lillian J Tuttle; Nicolas Cetraro; Courtney N Passow; Suzanne E McGaugh
Journal:  BMC Evol Biol       Date:  2018-06-18       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.